Physicians may want to reconsider goals for the treatment of plaque psoriasis. In this study, physicians describe utilizing treat-to-target with a patient-centered approach to care for symptom relief.
As the list of treatments for plaque psoriasis grows, so does the list of adverse events associated with biologic treatment. In this article, we summarize adverse events associated with common treatments for plaque psoriasis.
Brodalumab most cost-effective with high efficacy for plaque psoriasis, but IL-17 inhibitors as a whole outperform other biologics, study shows.
Twice-monthly certolizumab for plaque psoriasis could prove to be an option for patients who struggle with twice-weekly dosing, a study shows.
Dermatologists play a significant role in screening for psoriasis comorbidities and asking about shortness of breath as a routine part of medical history-taking, shows a study published in BMJ.